GLP-1 and GIP receptor agonists reduce mouse obesity in pre-clinical study
Treatment with Viking Therapeutics' dual agonists resulted in mean reductions…
Treatment with Viking Therapeutics' dual agonists resulted in mean reductions in body weight of up to 27 percent compared to semaglutide-treated animals.